Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Innoviva (HVE) Stock Price & Analysis

HVE Stock Chart & Stats

€19.00€0.30(1.60%)
At close: 1:00 AM GMT+1
€17€18€194 Sep22 Sep
Day’s Range
EUR 18.90 - EUR 19.00
52-Week Range
EUR 15.20 - EUR 21.20
Previous Close
EUR 18.70
Volume
N/A
Average Volume (3M)
13
Market Cap
EUR 1.37B
Enterprise Value
EUR 1.36B
Total Cash (Recent Filing)
EUR 579.06M
Total Debt (Recent Filing)
EUR 269.66M
Price to Earnings (P/E)
4.4
Beta
0.14
Next Earnings
Nov 11, 2026 (Est.)
EPS Estimate
0.46
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

High Cash Generation

Consistently strong operating and free cash flow indicate durable earnings quality and internal funding for R&D, acquisitions, or dividends. High cash conversion limits reliance on external financing and supports strategic flexibility over the next 2–6 months and beyond.

De-risked Balance Sheet

Material debt reduction and a larger equity base strengthen solvency and lower refinancing risk, improving financial flexibility. This makes the company better positioned to fund pipeline development or opportunistic investments without stressing liquidity.

Strategic Diversification: LYNX And Licensing Deals

Owning the LYNX platform and launching Nortiva creates a durable product-development avenue beyond royalties. Combined with licensing deals (e.g., Dr. Reddy’s for XACDURO), this expands addressable markets and creates multiple, long‑term commercial and milestone revenue streams.

Bears Say

Earnings Volatility

Large swings in margins suggest earnings are influenced by non‑recurring items or timing of investment gains, making forward cash flows less predictable. This undermines near‑term planning for capital allocation and could affect sustained payout or reinvestment policies.

Concentrated Royalty Reliance

Reliance on royalties from a few partnered respiratory franchises concentrates revenue risk. Long‑term cash generation depends on partners' commercialization, formulary access, and competitive dynamics, which Innoviva cannot fully control.

Historical Leverage Variability & Data Inconsistency

Past elevated leverage cycles plus inconsistencies in reported leverage metrics increase uncertainty about financial resilience under stress. This can complicate credit planning and raise refinancing or covenant risk during adverse periods.

Innoviva News

HVE FAQ

What was Innoviva’s price range in the past 12 months?
Innoviva lowest stock price was €15.20 and its highest was €21.20 in the past 12 months.
What is Innoviva’s market cap?
Innoviva’s market cap is €1.37B.
When is Innoviva’s upcoming earnings report date?
Innoviva’s next earnings report is estimated for Nov 11, 2026 (not yet confirmed), which is in 8 days.
How were Innoviva’s earnings last quarter?
Innoviva released its earnings results on Aug 05, 2026. The company reported -€1.021 earnings per share for the quarter, missing the consensus estimate of €0.39 by -€1.411.
Is Innoviva overvalued?
According to Wall Street analysts Innoviva’s price is currently Undervalued.
Does Innoviva pay dividends?
Innoviva does not currently pay dividends.
What is Innoviva’s EPS estimate?
Innoviva’s EPS estimate is 0.46.
How many shares outstanding does Innoviva have?
Innoviva has 72,245,480 shares outstanding.
What happened to Innoviva’s price movement after its last earnings report?
Innoviva reported an EPS of -€1.021 in its last earnings report, missing expectations of €0.39. Following the earnings report the stock price went down -2.222%.
Which hedge fund is a major shareholder of Innoviva?
Hedge funds hold Innoviva shares: the largest hedge-fund position in Innoviva is 1,151,067,448 shares, and hedge funds increased their holdings by 69.4K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology